Skip to main content




China grants country's first COVID-19 vaccine patent to CanSino: State media

China grants country's first COVID-19 vaccine patent to CanSino: State media

FILE PHOTO: Chinese vaccine maker CanSino Biologics' sign is pictured on its building in Tianjin, China November 20, 2018. Picture taken November 20, 2018. REUTERS/Stringer

BEIJING: China's vaccine specialist CanSino Biologics has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.

It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday (Aug 16).

The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug 11.

READ: Testing of CanSino's COVID-19 candidate vaccine begins in Russia

READ: China Sinopharm's potential COVID-19 vaccine triggers antibodies in clinical trials

Saudi Arabia said this month it plans to begin phase 3 clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.

CanSino's Hong Kong shares rose around 14 per cent in Monday's morning session. Its Shanghai shares rose by 6.6 per cent as of midday.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters


Also worth reading